(Sharecast News) - UK pharma group AstraZeneca on Thursday reported positive results from the Phase III VOLGA trial for its Imfinzi bladder cancer treatment.
High-level results from a planned interim analysis of the trial showed "meaningful improvements" in survival rates for muscle-invasive bladder cancer (MIBC) patients using Infinzi, otherwise known as...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE